Initially, 76 SCT, 85 ASCT and 161 CT patients were approached.Of these, 61, 69 and 118 patients respectively completed the baseline questionnaires at the time of study entry.We have previously reported HRQOL measured by European Organization for Treatment and Research of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).
The SCT group displayed greater changes from baseline scores than the ASCT group, with more symptoms in the first months post transplant.
A gradual improvement was found in both groups during the following 4–6 months, before stabilizing at baseline levels.
The reference group (CT group) received seven questionnaires in the first year after start of chemotherapy.
For practical reasons, the evaluation beyond the third anniversary since transplant was performed as a cross-sectional assessment.
Only minor changes were observed after the first year.
All groups reported more fatigue than the population values after 3 years (PIntensive high-dose chemotherapy (HDC) followed by allogeneic (SCT) or autologous (ASCT) stem cell transplantation is increasingly being used as a potentially curative treatment for various cancers and hematological diseases.
Over the years of follow-up, 16 SCT, 14 ASCT and 20 CT patients died, while seven, 13 and 38 patients respectively withdrew (10 CT patients received ASCT due to relapse after the first year).
If a questionnaire was missing but the patients stated that they were willing to continue in the study, they were not excluded.
Learn more, including about available controls: Cookies Policy.